Hypersensitivity reaction to rivaroxaban with a successful switch to apixaban: A case report.
Keyhan MohammadiRamin AnsariShakila YaribashPublished in: Clinical case reports (2024)
Hypersensitivity reactions to DOACs, though considered rare, have been documented. This report describes the case of a 28-year-old male with a history of testicular cancer who was recently diagnosed with deep vein thrombosis. He was referred to an outpatient pharmacotherapy clinic due to suspected rivaroxaban-induced cutaneous reactions. Following a thorough evaluation, his anticoagulant therapy was switched from rivaroxaban to apixaban. This change was successfully implemented, and no hypersensitivity symptoms recurred during subsequent follow-up. This case demonstrates the importance of recognizing potential adverse reactions to DOACs and illustrates the feasibility of switching anticoagulants under close medical supervision to ensure patient safety and effective treatment.
Keyphrases
- venous thromboembolism
- direct oral anticoagulants
- atrial fibrillation
- patient safety
- drug induced
- pulmonary embolism
- quality improvement
- papillary thyroid
- healthcare
- primary care
- high glucose
- diabetic rats
- squamous cell
- squamous cell carcinoma
- oxidative stress
- stem cells
- smoking cessation
- depressive symptoms
- adverse drug
- sleep quality
- cell therapy